• About
  • Contact
  • Resources
  • Book Nook
Donate
  • Featured
  • Commentary
  • Science & News
  • Mainstream
    • Mainstream Prevention
    • Mainstream Treatment
    • Vaccines
    • Repurposed Drugs
  • Integrative
    • Integrative Prevention
    • Integrative Treatments
    • Integrative Recovery
      • Long Haul
  • Controversies
    • Ivermectin
  • Blog
    • Michael Lerner’s Blog
    • Guest Authors
MenuClose
  • Featured
  • Commentary
  • Science & News
  • Mainstream Solutions
    • Mainstream Prevention
    • Mainstream Treatment
    • Vaccines
    • Repurposed Drugs
  • Integrative Therapies
    • Integrative Prevention
    • Integrative Treatments
    • Integrative Recovery
      • Long Haul
  • Controversies
    • Ivermectin
  • Blog
    • Guest Authors
    • Michael Lerner’s Blog
  • About
  • Contact
  • Resources
  • Donate
 — Article Category —

Mainstream Treatment


Time to Stop Using Ineffective Covid-19 Drugs

Time to Stop Using Ineffective Covid-19 Drugs

by Covid Strategies | Aug 18, 2022 | Featured, Ivermectin, Mainstream Treatment, Repurposed Drugs

By Salim S. Abdool Karim, M.B., Ch.B., Ph.D., and Nikita Devnarain, Ph.D. In practicing evidence-based medicine, physicians use the best evidence currently available on safety and efficacy in making decisions on treatment choices for their patients. During the...

read more
Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19

Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19

by Covid Strategies | Aug 18, 2022 | Controversies, Featured, Ivermectin, Mainstream Treatment

By Carolyn T. Bramante, M.D., M.P.H., et al. Abstract BACKGROUND Early treatment to prevent severe coronavirus disease 2019 (Covid-19) is an important component of the comprehensive response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic....

read more
FDA allows pharmacists to prescribe Paxlovid COVID treatment

FDA allows pharmacists to prescribe Paxlovid COVID treatment

by Covid Strategies | Jul 6, 2022 | Featured, Mainstream Treatment, Science & News

By Oriana Gonzalez The Food and Drug Administration said Wednesday it's allowing state-authorized pharmacists to prescribe Pfizer's antiviral treatment Paxlovid. Driving the news: It's a win for pharmacies, which had been pushing for the FDA to allow...

read more
What Is ‘Paxlovid Rebound’? CDC Warns of COVID-19 Recurrence After Antiviral Treatment

What Is ‘Paxlovid Rebound’? CDC Warns of COVID-19 Recurrence After Antiviral Treatment

by Covid Strategies | Jun 1, 2022 | Featured, Mainstream Treatment, Science & News

The recurring symptoms are usually milder than the initial illness—but you may still be contagious. By Julia Ries  Some patients who have taken Pfizer's Paxlovid medication—an antiviral drug used to prevent severe illness from COVID-19—have experienced a recurrence in...

read more
Rebound COVID Is Just the Start of Paxlovid’s Mysteries

Rebound COVID Is Just the Start of Paxlovid’s Mysteries

by Covid Strategies | May 26, 2022 | Featured, Mainstream Treatment

There’s plenty more to learn about the lifesaving antiviral COVID treatment.   By Rachel Gutman The first data on Paxlovid, out last November, hinted that the COVID antiviral would cut the risk of hospitalization and death by 89 percent. Pundits called the drug...

read more
FDA rebukes Pfizer CEO’s suggestion to take more Paxlovid if COVID-19 symptoms return

FDA rebukes Pfizer CEO’s suggestion to take more Paxlovid if COVID-19 symptoms return

by Covid Strategies | May 5, 2022 | Featured, Mainstream Treatment, Science & News

By Zoey Becker The FDA rebuked Pfizer CEO Albert Bourla’s proposed solution to reports that some patients experienced a relapse of COVID-19 symptoms after treatment with the company's antiviral Paxlovid. After reports said some patients who took Paxlovid rebounded and...

read more
NIAID Sponsored Study: Hyperimmune Intravenous Immunoglobulin & Remdesivir Fails to Beat Remdesivir as COVID-19 Treatment

NIAID Sponsored Study: Hyperimmune Intravenous Immunoglobulin & Remdesivir Fails to Beat Remdesivir as COVID-19 Treatment

by Covid Strategies | Jan 29, 2022 | Mainstream Treatment, Science & News

Recently, an international trial site network known as the International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) completed a global study revealing that remdesivir plus a highly concentrated solution of antibodies that neutralize SARS-CoV-2...

read more
TFF Pharmaceuticals Advancing Niclosamide, an Inhaled COVID-19 Treatment with Potential Activity Against Multiple Variants

TFF Pharmaceuticals Advancing Niclosamide, an Inhaled COVID-19 Treatment with Potential Activity Against Multiple Variants

by Covid Strategies | Jan 28, 2022 | Mainstream Treatment, Science & News

TFF Pharmaceuticals announced it has completed enrollment of 40 healthy subjects in its Phase 1 clinical trial of a dry powder formulation of niclosamide, an antiviral treatment with potential to address COVID-19 and other respiratory viral diseases. TFF develops...

read more
Paxlovid Cleared for Conditional Use in Europe

Paxlovid Cleared for Conditional Use in Europe

by Covid Strategies | Jan 27, 2022 | Mainstream Treatment, Science & News

Paxlovid, the oral Pfizer treatment for COVID-19, appears headed for emergency use authorization in Europe.  Conditional Marketing Authorization for Paxlovid The European Medical Agency’s (EMA) human medicines committee (CHMP) recommended Pfizer Europe MA EEIG...

read more
Merck’s COVID-19 pill to be produced by more than two dozen drugmakers

Merck’s COVID-19 pill to be produced by more than two dozen drugmakers

by Covid Strategies | Jan 20, 2022 | Featured, Mainstream Solutions, Mainstream Treatment

BY MONIQUE BEALS Medicines Patent Pool, an organization supported by the U.N., announced on Thursday that over two dozen generic drug makers will soon begin producing Merck's COVID-19 pill to make the treatment more accessible in developing...

read more
Researchers report potential broad-spectrum anti-coronavirus cocktail therapy

Researchers report potential broad-spectrum anti-coronavirus cocktail therapy

by Covid Strategies | Jan 19, 2022 | Featured, Integrative Treatments, Mainstream Treatment

A research team led by Professor Hongzhe Sun, Norman & Cecilia Yip Professor in Bioinorganic Chemistry from the Department of Chemistry, Faculty of Science, the University of Hong Kong (HKU), in collaboration with Dr. Shuofeng Yuan, Assistant Professor from the...

read more
Fauci warns of ‘urgent need’ for super vaccine as other variants emerge

Fauci warns of ‘urgent need’ for super vaccine as other variants emerge

by Covid Strategies | Jan 11, 2022 | Mainstream Prevention, Mainstream Solutions, Mainstream Treatment, Vaccines

New variants will pose continued threat, NIAID chief warns By John Bowden, Megan Sheets Dr Anthony Fauci warned at a Senate committee hearing that the US faced an “urgent need” for a so-called super vaccine that would be more effective at preventing new variants of...

read more
COVID-19 Omicron Variant Resistant to Monoclonal Antibodies – But Neutralized by Vaccine Booster

COVID-19 Omicron Variant Resistant to Monoclonal Antibodies – But Neutralized by Vaccine Booster

by Covid Strategies | Jan 9, 2022 | Featured, Mainstream Treatment, Vaccines

By INSTITUT PASTEUR The Omicron variant was detected for the first time in South Africa in November 2021 and has since spread to many countries. It is expected to become the dominant variant within a few weeks or months. Initial epidemiological studies show that the...

read more
Colchicine Flops for In-Hospital COVID

Colchicine Flops for In-Hospital COVID

by Covid Strategies | Dec 31, 2021 | Featured, Mainstream Solutions, Mainstream Treatment, Repurposed Drugs

— No reduced risk of mechanical ventilation or death by Zaina Hamza Colchicine (Colcrys) didn't benefit patients hospitalized with moderate to severe COVID-19-related pneumonia, researchers found in the COLCOVID randomized trial. Among more than 1,200 COVID-19...

read more
Doctor Submits Fluvoxamine EUA Application to FDA

Doctor Submits Fluvoxamine EUA Application to FDA

by Covid Strategies | Dec 29, 2021 | Featured, Mainstream Solutions, Mainstream Treatment, Repurposed Drugs

— Group of physician-scientists believes data support authorization for treating COVID-19 by Sophie Putka t took about 4 days for David Boulware, MD, MPH, to write the FDA emergency use authorization (EUA) application for fluvoxamine. Yes, a doctor wrote an EUA...

read more
Page 1 of 41234»

Address:

Commonweal P.O Box 316 | Bolinas, CA 94924

Latest Covid news in your inbox!

Success!

Subscribe

Search Articles

©2021 CovidStrategies/Commonweal | Site maintained by Mercury Multimedia

Privacy Policy | Home